Zobrazeno 1 - 10
of 121
pro vyhledávání: '"Kalkunte S. Srivenugopal"'
Publikováno v:
Cells, Vol 13, Iss 15, p 1272 (2024)
Human NAD(P)H-quinone oxidoreductase1 (HNQO1) is a two-electron reductase antioxidant enzyme whose expression is driven by the NRF2 transcription factor highly active in the prooxidant milieu found in human malignancies. The resulting abundance of NQ
Externí odkaz:
https://doaj.org/article/81f67f9972c74e4f8ff56e350ec1b973
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 4, Pp 305-323 (2018)
Whether the antimutagenic DNA repair protein MGMT works solo in human cells and if it has other cellular functions is not known. Here, we show that human MGMT associates with PCNA and in turn, with the cell cycle inhibitor, p21cip1 in glioblastoma an
Externí odkaz:
https://doaj.org/article/188c8ca4ac824ea7b6c4851b2b0de682
Autor:
Surendra R. Punganuru, Viswanath Arutla, Wei Zhao, Mehrdad Rajaei, Hemantkumar Deokar, Ruiwen Zhang, John K. Buolamwini, Kalkunte S. Srivenugopal, Wei Wang
Publikováno v:
Cells, Vol 9, Iss 7, p 1592 (2020)
There is a desperate need for novel and efficacious chemotherapeutic strategies for human brain cancers. There are abundant molecular alterations along the p53 and MDM2 pathways in human glioma, which play critical roles in drug resistance. The prese
Externí odkaz:
https://doaj.org/article/0aba6ac868e54a4a99c45cc966adebbf
Publikováno v:
Cancer Research. 83:457-457
NAD(P)H-quinone oxidoreductase 1 (NQO1) is a rational target for designing tumor-selective anticancer therapies because the 2-electron reductase is expressed at very low levels in normal tissues but present abundantly (5 to 200-fold) in human cancers
Publikováno v:
Cancer Research. 82:1826-1826
Background: Disulfiram (DSF) in combination with copper pills has emerged as a safe and exciting anticancer strategy and is undergoing clinical trials in multiple human cancers. However, DSF breaks down in the gut or blood immediately and chances of
Autor:
Racheal G, Akwii, Md S, Sajib, Fatema T, Zahra, Hanumantha R, Madala, Kalkunte S, Srivenugopal, Constantinos M, Mikelis
Publikováno v:
Methods in molecular biology (Clifton, N.J.). 2193
Lymphangiogenesis, the formation of lymphatic vessels from preexisting ones, is an important process in wound-healing physiology. Deregulation of lymphangiogenesis and lymphatic vascular remodeling have been implicated in a range of inflammatory cond
Autor:
Hanumantha Rao Madala, Fatema Tuz Zahra, Racheal G Akwii, Kalkunte S. Srivenugopal, Sanaullah Sajib, Constantinos M. Mikelis
Publikováno v:
Methods in Molecular Biology ISBN: 9781071608449
Lymphangiogenesis, the formation of lymphatic vessels from preexisting ones, is an important process in wound-healing physiology. Deregulation of lymphangiogenesis and lymphatic vascular remodeling have been implicated in a range of inflammatory cond
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::77a7d4f54955d848d421aa6df4268101
https://doi.org/10.1007/978-1-0716-0845-6_9
https://doi.org/10.1007/978-1-0716-0845-6_9
Autor:
Ameya Paranjpe, Santhi D. Konduri, Joshua Smith, Sheila Jeudy, Richard A. Rovin, George C. Bobustuc, Maharaj Singh, Amin B. Kassam, Kalkunte S. Srivenugopal, Beth Isley
Publikováno v:
Oncotarget
The DNA damage repair enzyme, O6-methylguanine DNA methyltransferase (MGMT) is overexpressed in breast cancer, correlating directly with estrogen receptor (ER) expression and function. In ER negative breast cancer the MGMT promoter is frequently meth
Publikováno v:
Neoplasia: An International Journal for Oncology Research, Vol 20, Iss 4, Pp 305-323 (2018)
Whether the antimutagenic DNA repair protein MGMT works solo in human cells and if it has other cellular functions is not known. Here, we show that human MGMT associates with PCNA and in turn, with the cell cycle inhibitor, p21cip1 in glioblastoma an
Autor:
Surendra R. Punganuru, Francis Ali-Osman, Hanumantha Rao Madala, Kalkunte S. Srivenugopal, Ruiwen Zhang
Publikováno v:
Oncotarget
There is great interest in repurposing disulfiram (DSF), a rapidly metabolizing nontoxic drug, for brain cancers and other cancers. To overcome the instability and low therapeutic efficacy, we engineered passively-targeted DSF-nanoparticles (DSFNPs)